Navigation Links
ENMD in Medical News

EntreMed Reports Second Quarter 2009 Financial Results

... ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six...

EntreMed Reports First Quarter 2009 Financial Results

... ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...

EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results

... ROCKVILLE, Md., March 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

EntreMed Focuses on Development of ENMD-2076

...agement Realigned to Provide Full Support for Clinical Activities ROCKVILLE, Md., Dec. 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company announced today plans to focus the Company's resources on its most promising near-term product candidate, E...

EntreMed Reports Clinical Program Progress and Company Update

... ROCKVILLE, Md., Nov. 12, /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, reported corporate and clini...

EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

... ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program

... Additional Resources to Accelerate ENMD-2076 Partnering Efforts ROCKVILLE, Md., Aug. 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the BIO 2008 Annual International Convention

... ROCKVILLE, Md., June 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference

... ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

Dr. Ronald E. Cape to Retire from EntreMed Board of Directors

... ROCKVILLE, Md., April 7, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the retireme...
ENMD in Medical Technology

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...ded Clinical Program Now Includes Solid and Hematological Malignancies ROCKVILLE, Md., June 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for i...

EntreMed Presents Initial Clinical Results for ENMD-2076

...ug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced recent devel...

EntreMed Receives New Patent for 2-Methoxyestradiol Analogs

... Patent Covers Compositions and Methods ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

... Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

...pounds Demonstrate Potent Antitumor Activity in a Variety of Tumor Types ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

...ral Presentation During the "New Drugs on the Horizon 2" Special Session ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it will pres...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

...elective Kinase Inhibitor Phase 1 Trial in Advanced Cancer Patients ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Continuous Dosing Clinical Trial For MKC-1

... Phase 1 Study to be Conducted in Advanced Cancer Patients ROCKVILLE, Md., April 2, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers

... Multi-Center Clinical Trial to be Conducted in Canada ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the commence...

EntreMed to Present at The New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Dec. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....
ENMD in Biological Technology

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

...nical Program Adds Leukemia Clinical Study and Orphan Drug Designation ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for three of its clinical...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Compa...

EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

... Phase 2 Randomized Study Under Consideration ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Third Quarter 2008 Financial Results

... ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models

... ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publicat...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

... ROCKVILLE, Md., Oct. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Present at BioPartnering Europe Conference

... ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H...

EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market

... ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Second Quarter 2008 Financial Results

... EntreMed to Conduct Update Call on Tuesday, August 12, 2008 ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...
Other Tags
(Date:12/22/2014)... Fad diets have been around forever ... most fad diets have hung around so long is that ... is that, as the body becomes accustomed to new eating ... to reset the metabolism to return the body to fast ... all-inclusive diet plans that are medically supervised throughout. ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting company, ... ad hoc report writing service to meet the high ... for an annual subscription and get a fixed number ... discounted hourly rate. , Customers can choose from ... rate. Subscription hours are contracted in 25 hour increments. ...
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... SUNDAY, Dec. 21, 2014 (HealthDay News) -- A new ... cow disease" in deer might also protect livestock and ... The vaccine appears to help prevent deer from becoming ... wasting disease, according to the report in the Dec. ... Chronic wasting disease is caused by mysterious infectious particles ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
Other Contents